Extended-pulsed Dosing of Fidaxomicin vs. Standard-dose Vancomycin for Clostridium difficile Infection

    loading  Checking for direct PDF access through Ovid

Abstract

A randomized, controlled, open-label clinical trial conducted at 86 European hospitals that included adults aged 60 years or older found that extended-pulsed dosing of fidaxomicin was superior to standard-dose vancomycin for sustained cure of Clostridium difficile infection and resulted in fewer disease recurrences.

Related Topics

    loading  Loading Related Articles